Unlike with PD-L1 scores, the CD8Teff score integrates multiple complex factors within the TME, including interactions with DCs, CAFs, cancer cells, NK cells and cytokines, offering a more accurate characterization of tumor immune activity and therapy response. This evidence concerns the gene CD274 and cancer.